Quantum-First Trial: <i>FLT3</i>-ITD-Specific MRD Clearance Is Associated with Improved Overall SurvivalMark J. Levis, Alexander E. Perl, Jianxiang Wang et al.|Blood|2022Cited by 9
<i>FLT3</i> -ITD measurable residual disease from the QuANTUM-First trialMark J. Levis, Alexander E. Perl, Harry P. Erba et al.|Blood Advances|2025Cited by 7
Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( <i>FLT3</i>-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction (IND) and Consolidation (CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) <i>FLT3</i>-ITD+ AML Patients (pts)Alexander E. Perl, Mark J. Levis, Harry P. Erba et al.|Blood|2023Cited by 5
P483: QUANTUM-FIRST TRIAL: FLT3-ITD–SPECIFIC MEASURABLE RESIDUAL DISEASE (MRD) CLEARANCE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVALMark J. Levis, Alexander E. Perl, Harry P. Erba et al.|HemaSphere|2023Cited by 3
Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With <i>FLT3</i>-ITD-Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First TrialMark J. Levis, Harry P. Erba, Pau Montesinos et al.|Blood|2024Cited by 2